» Articles » PMID: 23041721

Xenograft Models of Chronic Lymphocytic Leukemia: Problems, Pitfalls and Future Directions

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 2012 Oct 9
PMID 23041721
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Xenotransplantation of human tumor cells into immunodeficient mice has been a powerful preclinical tool in several hematological malignancies, with the notable exception of chronic lymphocytic leukemia (CLL). For several decades, this possibility was hampered by the inefficient and/or short-term engrafment of CLL cells into available animals. The development of new generations of immunocompromised mice has allowed to partially overcome these constraints. Novel humanized animal models have been created that allow to recapitulate the pathogenesis of the disease and the complex in vivo relationships between leukemic cells and the microenvironment. In this review we discuss the development of xenograft models of CLL, how they may help elucidating the mechanisms that account for the natural history of the disease and facilitating the design of novel therapeutic approaches.

Citing Articles

Targeting chronic lymphocytic leukemia with B-cell activating factor receptor CAR T cells.

Qie Y, Gadd M, Shao Q, To T, Liu A, Li S MedComm (2020). 2024; 5(9):e716.

PMID: 39224539 PMC: 11366826. DOI: 10.1002/mco2.716.


Mutation-specific CAR T cells as precision therapy for IGLV3-21 expressing high-risk chronic lymphocytic leukemia.

Markl F, Schultheiss C, Ali M, Chen S, Zintchenko M, Egli L Nat Commun. 2024; 15(1):993.

PMID: 38307904 PMC: 10837166. DOI: 10.1038/s41467-024-45378-w.


Understanding CLL biology through mouse models of human genetics.

Ten Hacken E, Wu C Blood. 2021; 138(25):2621-2631.

PMID: 34940815 PMC: 8703365. DOI: 10.1182/blood.2021011993.


Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia.

Ecker V, Stumpf M, Brandmeier L, Neumayer T, Pfeuffer L, Engleitner T Nat Commun. 2021; 12(1):3526.

PMID: 34112805 PMC: 8192787. DOI: 10.1038/s41467-021-23752-2.


Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL.

Cuesta-Mateos C, Juarez-Sanchez R, Mateu-Albero T, Loscertales J, Mol W, Terron F MAbs. 2021; 13(1):1917484.

PMID: 33944659 PMC: 8098074. DOI: 10.1080/19420862.2021.1917484.